Clinical Trial Update: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating PDR001 plus LAG525 in patients with advanced solid and hematologic malignancies; results posted with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration Resistant Prostate Adenocarcinoma
• Diffuse Large B-cell Lymphoma
• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Ovarian Adenocarcinoma
• Small Cell Lung Cancer
• Soft Tissue Sarcoma
• Well-differentiated Neuroendocrine Tumors

Drugs mentioned

• LAG525
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Small Cell Lung Cancer, Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-19